Nektar Therapeutics (NKTR) Other Non-Current Liabilities (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Other Non-Current Liabilities of $8.4 million for Q1 2026, up 25.01% year-over-year from $6.8 million in Q1 2025, and down 2.08% quarter-over-quarter from $8.6 million in Q4 2025.
Nektar Therapeutics (NKTR) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Other Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $8.4 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 25.01% year-over-year to $8.4 million; the TTM figure through Mar 2026 stood at $8.4 million (up 25.01% YoY), while the FY2025 annual figure was $8.6 million, up 19.11% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $8.4 million, down from $8.6 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $8.6 million in Q4 2025, with the low at $2.1 million in Q2 2022.
- The 5-year median for Other Non-Current Liabilities is $6.5 million (2023), against an average of $6.1 million.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities slumped 48.21% in 2022, then jumped 147.64% in 2023.
- Nektar Therapeutics' Other Non-Current Liabilities stood at $7.6 million in 2022, then sank by 38.62% to $4.6 million in 2023, then soared by 56.22% to $7.2 million in 2024, then advanced by 19.11% to $8.6 million in 2025, then declined by 2.08% to $8.4 million in 2026.
- Business Quant data shows NKTR's Other Non-Current Liabilities at $8.4 million in Q1 2026, $8.6 million in Q4 2025, and $5.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.45 Mn |
| Dec 31, 2025 | 8.63 Mn |
| Sep 30, 2025 | 5.03 Mn |
| Jun 30, 2025 | 5.64 Mn |
| Mar 31, 2025 | 6.76 Mn |
| Dec 31, 2024 | 7.24 Mn |
| Sep 30, 2024 | 6.91 Mn |
| Jun 30, 2024 | 8.05 Mn |
| Mar 31, 2024 | 4.33 Mn |
| Dec 31, 2023 | 4.64 Mn |
| Sep 30, 2023 | 4.96 Mn |
| Jun 30, 2023 | 5.15 Mn |
| Mar 31, 2023 | 6.48 Mn |
| Dec 31, 2022 | 7.55 Mn |
| Jun 30, 2022 | 2.08 Mn |
| Dec 31, 2021 | 3.59 Mn |
| Sep 30, 2021 | 21.39 Mn |
| Jun 30, 2021 | 4.02 Mn |
| Mar 31, 2021 | 4.60 Mn |
| Sep 30, 2020 | 3.29 Mn |